Combigan is a prescription eye drop combining brimonidine and timolol, FDA-approved since 2007 for open-angle glaucoma and ocular hypertension. The dual-ingredient formula targets elevated intraocular pressure through two complementary mechanisms in one convenient twice-daily bottle.
The drug reduces IOP by 4.4 to 7.6 mmHg from baseline in clinical studies with 1,159 subjects. It consolidates brimonidine and timolol into one twice-daily drop, which simplifies adherence. User reviews are mixed: 42% positive on Drugs.com, with documented outcomes ranging from dramatic pressure drops to severe allergic reactions and near-fainting episodes.
This review covers what Combigan is, how its dual mechanism works, who should and shouldn’t use it, real patient experiences from Drugs.com and WebMD, how it compares to Lumigan and Cosopt, its cost, the generic option available since 2022, and the bottom-line verdict on whether the evidence supports it.
What Are Combigan Eye Drops?
Combigan is a brand-name prescription eye drop combining brimonidine and timolol, FDA-approved in 2007 for glaucoma and ocular hypertension. The drug class spans two categories: brimonidine is an alpha-2 adrenergic agonist and timolol is a beta blocker. Two different mechanisms. One bottle.
In 2020, Combigan ranked as the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions filled. That’s not a niche drug. That volume reflects its well-established place in glaucoma treatment protocols nationwide.
Combigan is approved for adults and children 2 years and older who require adjunctive or replacement therapy for inadequately controlled intraocular pressure. Doctors prescribe it when a single medication can’t keep eye pressure in the target range.
What Ingredients Does Combigan Contain?
Combigan contains brimonidine tartrate 0.2% (2 mg per 1 mL) and timolol maleate 0.5% (5 mg per 1 mL) in a sterile ophthalmic solution. These are the standard therapeutic strengths used in FDA clinical trials and carried forward into the approved product.
Here’s what else is in it: key inactive ingredients include benzalkonium chloride (a preservative), sodium phosphate, and purified water. The benzalkonium chloride can discolor soft contact lenses. That’s why Combigan must go in before lenses, not after.
Combigan comes in three bottle sizes: 5 mL (1/6 oz), 10 mL (1/3 oz), and 15 mL (1/2 oz). Each opened bottle must be discarded after 28 days regardless of how much is left. It’s not about the quantity. It’s about bacterial contamination risk that builds over time.
Key Drug Facts:
| Property | Detail |
|---|---|
| Brand Name | Combigan |
| Drug Class | Alpha agonist / Beta blocker |
| Active Ingredients | Brimonidine tartrate 0.2% + Timolol maleate 0.5% |
| Dosing Frequency | Twice daily (12 hours apart) |
| Controlled Substance | No |
| Availability | Prescription only |
How Does Combigan Lower Eye Pressure?
Timolol is a beta-adrenergic blocker that lowers intraocular pressure by reducing the production of aqueous humor inside the eye. Aqueous humor is the clear fluid that fills the front portion of the eye. Too much of it means higher pressure.
Brimonidine is an alpha-2 adrenergic agonist that takes a dual approach. It reduces aqueous humor production and simultaneously increases its outflow drainage from the eye. That second mechanism is what sets brimonidine apart from timolol.
Together, the two components act through complementary pathways. The result? Additive IOP reduction greater than either drug alone. In a 12-month clinical study with 1,159 subjects, Combigan lowered IOP by 4.4 to 7.6 mmHg from baseline values.
What Conditions Does Combigan Treat?
Combigan is FDA-approved for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who require adjunctive or replacement therapy. The drug label specifies this second-line positioning clearly.
Open-angle glaucoma occurs when elevated intraocular pressure damages the optic nerve, which helps eyes and brain communicate. The optic nerve damage is progressive. It can lead to permanent vision loss if it goes untreated or under-treated.
Ocular hypertension is different. It means eye pressure is elevated above normal, but without optic nerve damage present yet. Combigan reduces this pressure to decrease the risk of progression from ocular hypertension into full glaucoma with nerve damage.
Is Combigan Approved for Use in Children?
Yes. Combigan is approved for children 2 years of age and older, but it’s strictly contraindicated in children under 2 years old. The age cutoff reflects a specific safety risk tied to brimonidine, not timolol.
In children under 2, brimonidine can cause respiratory depression (slowed breathing), slowed heartbeat, low blood pressure, low body temperature, and drowsiness. These risks are serious enough that the FDA placed a hard contraindication on this entire age group.
What Are the Benefits of Combigan?
Combigan combines two drugs in one bottle, simplifying the dosing regimen for patients who would otherwise need to use brimonidine and timolol as separate prescriptions. Fewer bottles. Fewer daily applications. Less burden for a condition that requires medication every single day.
The two active ingredients work via different pathways. That’s the point. Working through different mechanisms provides more effective IOP control than either drug alone. Clinical data shows Combigan achieves 1 to 3 mmHg greater IOP reduction than brimonidine alone at most measured time points.
And here’s an often-overlooked advantage: a 2006 double-blind clinical trial found Combigan caused fewer systemic side effects such as low blood pressure and slow heart rate compared to the same components administered concurrently as separate drops. The fixed combination appears to offer a more stable systemic exposure profile.
Key Benefits of Combigan:
- Combines two drugs in one bottle for simplified daily dosing
- Reduces IOP 1 to 3 mmHg more than brimonidine monotherapy
- Approved for both adults and children 2 years and older
- Fewer systemic side effects than taking both drugs separately
- Available as a lower-cost generic since 2022
Does Combigan Effectively Reduce Intraocular Pressure?
Yes. Combigan achieves clinically meaningful IOP reduction: in a 12-month study with 1,159 subjects, the drug lowered intraocular pressure by 4.4 to 7.6 mmHg from baseline values when dosed twice daily. One documented patient reduced pressure from 43 mmHg to 12 mmHg after 6 months of use. That’s a dramatic outcome.
Compared to brimonidine 0.2% dosed three times daily, Combigan reduced IOP by 1 to 3 mmHg more at most time points. The one exception? At 5 p.m., no significant difference existed, because the brimonidine group received its mid-afternoon dose between 3 p.m. and 5 p.m.
According to Combigan product information, IOP lowering was 1 to 2 mmHg less than concomitant administration of both components as separate drops. The slight trade-off in efficacy is offset by the convenience and improved adherence that the fixed combination provides.
How Does Combigan Compare to Using Two Separate Drops?
Combigan replaces two separate prescriptions (brimonidine three times daily and timolol twice daily) with a single drop applied twice daily, reducing the total number of daily eye drop applications. This consolidation is a meaningful quality-of-life improvement for patients managing glaucoma long term.
But here’s the trade-off: Combigan’s IOP lowering is 1 to 2 mmHg less than the concomitant administration of timolol 0.5% twice daily and brimonidine 0.2% three times daily taken as separate drops. Patients with very high target pressures may need the maximally dosed separate regimen instead.
Fixed-combination drugs like Combigan improve patient adherence by reducing the number of bottles and administration steps. Poor adherence is a major problem in glaucoma treatment. Patients often don’t feel a difference in daily life, yet must medicate consistently to prevent vision loss that can’t be reversed.
What Do Combigan Reviews Say?
Combigan has an average rating of 5.0 out of 10 from 26 reviews on Drugs.com, with 42% of reviewers reporting a positive experience and 46% reporting a negative experience. That near-even split is telling. This is a medication that works extremely well for some patients and causes significant problems for others.
On WebMD, Combigan holds a 3.1 out of 5 average rating from 65 reviews, with approximately 63% of reviewers reporting a positive effect. The higher volume on WebMD provides a broader picture of real-world patient experience with this drug.
On Sermo, a platform with ratings added by triple-verified physicians, Combigan receives consistent recognition as an effective combination agent. Physicians focus more on IOP reduction efficacy while noting the drug’s side effect profile in a clinical, measured way that differs from patient-written reviews.
What Positive Experiences Do Combigan Users Report?
Positive Combigan users most frequently report significant and sustained intraocular pressure reduction as the primary benefit. One reviewer documented a pressure drop from 43 mmHg to 12 mmHg after 6 months with no notable side effects, calling the result ‘fantastic.’ That’s the kind of outcome Combigan is capable of.
Other positive reviewers highlight the convenience of combining two drugs in one bottle, particularly those who previously managed multiple separate eye drops. Several report that initial stinging fades quickly and that the long-term pressure control justifies continued use.
What Are the Most Common Complaints About Combigan?
The most common negative reports involve systemic side effects from the beta blocker component entering the bloodstream through the tear ducts. Multiple reviewers describe near-fainting episodes, with one switching to Azarga (brinzolamide/timolol) after three such events. Not a minor inconvenience.
Allergic reactions appear in multiple reviews: users report dark red swollen eyelids, severe pain and burning, and significant eye discharge. One reviewer stated they’d rather take no eye drop at all than continue Combigan due to the severity of the allergic response.
A recurring design complaint targets the bottle tip: the opening is too large. Too much solution dispenses per squeeze. Patients using drops in both eyes report emptying a 5 mL bottle in 2 weeks rather than the expected 4 weeks. That’s a real cost issue.
How Does Combigan Compare to Alternatives?
The main alternatives to Combigan include Lumigan (bimatoprost), Cosopt and Cosopt PF (dorzolamide/timolol), Simbrinza (brinzolamide/brimonidine), and individual monotherapy drops like Xalatan (latanoprost). Each targets elevated IOP through a different mechanism.
Prostaglandin eye drops such as Lumigan and Xalatan are generally first-choice options for glaucoma per specialist guidelines. Combigan is approved and labeled as adjunctive or second-line therapy, meaning it fills an important role for patients whose IOP remains uncontrolled on a prostaglandin alone.
Combigan vs. Common Alternatives:
| Medication | Drug Class | Dosing | Use Position |
|---|---|---|---|
| Combigan | Alpha agonist + Beta blocker | Twice daily | Second-line / adjunctive |
| Lumigan (bimatoprost) | Prostaglandin analog | Once daily | First-line |
| Xalatan (latanoprost) | Prostaglandin analog | Once daily (night) | First-line |
| Cosopt (dorzolamide/timolol) | CAI + Beta blocker | Twice daily | Second-line / adjunctive |
| Simbrinza (brinzolamide/brimonidine) | CAI + Alpha agonist | Three times daily | Second-line / adjunctive |
Combigan vs. Lumigan: Which Works Better?
Lumigan (bimatoprost) is a prostaglandin analog instilled once daily, while Combigan contains an alpha agonist and a beta blocker and is used twice daily. The two drugs work through entirely different mechanisms and address different positions in the treatment ladder.
Lumigan and other prostaglandins are generally first-choice options for glaucoma because they’re highly effective and well-tolerated. Combigan is used as adjunctive therapy when a single drug such as Lumigan isn’t sufficient to reach the target IOP. They’re not head-to-head competitors. They’re partners.
Eye specialists sometimes prescribe Combigan and latanoprost (Xalatan, a prostaglandin similar to Lumigan) together. In this combined protocol, latanoprost is applied once at night while Combigan is used twice daily, spaced at least 5 minutes apart when doses overlap.
Combigan vs. Cosopt: What Is the Difference?
Cosopt contains dorzolamide (a carbonic anhydrase inhibitor) and timolol, while Combigan contains brimonidine (an alpha-2 agonist) and timolol. Both share the timolol beta blocker component but differ in their second active ingredient.
Here’s the thing: Cosopt PF, a preservative-free version of Cosopt, is available for patients who experience irritation from benzalkonium chloride. Standard Combigan contains benzalkonium chloride and doesn’t currently have a widely available preservative-free formulation. For sensitive patients, Cosopt PF has a real advantage.
What Side Effects Does Combigan Cause?
Common Combigan side effects include eye redness, itching, dryness, stinging upon application, dry mouth, and dizziness. The dry mouth side effect can be managed by drinking water regularly or chewing sugarless gum. These are the mild ones. They’re manageable for most patients.
Eye drops leak from the tear ducts into the bloodstream after application. The timolol beta blocker follows this route and can produce systemic effects including low blood pressure, slowed heart rate, and episodes of near-fainting in susceptible patients. That’s not a theoretical risk. It’s documented in real patient reviews.
Combigan may also cause increased light sensitivity in the eyes and drowsiness. The manufacturer recommends wearing dark glasses outdoors and avoiding driving or operating machinery until patients understand how the medication affects their alertness and vision.
Common vs. Serious Side Effects:
| Common (Mild) | Serious (Seek Medical Attention) |
|---|---|
| Eye redness and itching | Near-fainting or loss of consciousness |
| Stinging upon application | Severe allergic reaction (swelling, severe pain) |
| Dry mouth | Slowed heartbeat or low blood pressure |
| Dizziness | Difficulty breathing (bronchospasm) |
| Light sensitivity | Significant visual disturbance |
| Drowsiness | Dark red discoloration of eyelids |
What Serious Side Effects Can Combigan Cause?
Serious cardiovascular effects represent the most clinically significant risk from Combigan, driven by systemic absorption of the timolol component through nasolacrimal drainage. Multiple patient accounts describe near-fainting episodes, and one reviewer reported developing chronic high blood pressure as the body compensated for the beta-blocking effect. Pay attention to this.
Severe allergic reactions are documented: eye and eyelid redness turning dark, severe pain, burning, and swelling severe enough that affected patients discontinued the medication immediately. Any sign of serious allergic reaction requires stopping the drug and seeking urgent medical evaluation.
Rare but serious reports include significant visual disturbance lasting days after the first dose, and one case of losing 80% of hair. These outcomes are uncommon. But they underscore why medical supervision and prompt reporting of unexpected symptoms matter throughout the course of treatment.
Who Should Avoid Combigan?
Combigan is contraindicated in patients with a history of asthma or chronic obstructive pulmonary disease (COPD), because the timolol beta blocker component can trigger bronchospasm in airways already sensitive to such agents.
Patients with serious heart conditions including AV block, severe heart failure, or bradycardia (slow heartbeat) that has caused fainting must not use Combigan. The systemic beta blockade from timolol absorption can worsen these cardiac conditions in dangerous ways.
Children under 2 can’t use Combigan. And caution is required with MAO inhibitors, tricyclic antidepressants, digoxin, calcium channel blockers, and CYP2D6 inhibitors, because drug interactions with these classes can amplify cardiovascular effects or alter brimonidine clearance significantly.
Who Should Not Use Combigan:
- Patients with a history of asthma or COPD
- Patients with AV block, severe heart failure, or bradycardia
- Children under 2 years of age
- Patients allergic to brimonidine or timolol
- Patients currently using MAO inhibitors
How Should You Use Combigan Eye Drops?
To apply Combigan, tilt the head back slightly, pull down the lower eyelid to form a small pocket, hold the dropper tip down above the eye, look up and away from the dropper tip, and squeeze one drop into the pocket. Wash hands before every application. That step isn’t optional.
Store Combigan at room temperature away from moisture and heat; don’t freeze it. Keep the bottle tightly closed when not in use. Each bottle must be discarded 28 days after opening because prolonged storage after first use increases the risk of bacterial contamination in the solution.
Steps to Apply Combigan Correctly:
- Wash hands thoroughly with soap and water before handling the bottle.
- Tilt the head back slightly and pull the lower eyelid down to form a small pocket.
- Hold the dropper tip down above the eye without touching it to any surface.
- Look up and away from the dropper, then squeeze one drop into the lower lid pocket.
- Close the eye gently for 1 to 2 minutes and press lightly on the inner corner to reduce drainage.
- Wait at least 5 minutes before applying any other eye medication.
How Often Should You Apply Combigan?
Combigan is applied one drop in the affected eye twice daily, approximately 12 hours apart. This twice-daily schedule is simpler than brimonidine monotherapy, which requires three daily applications to maintain consistent IOP control. That’s one fewer daily application, every day, for what is typically a lifelong condition.
When using other eye medications alongside Combigan, patients must wait at least 5 minutes between each drop. This spacing prevents one drop from washing out the other before proper absorption occurs, ensuring both medications are fully effective.
What if a dose is missed? Apply it as soon as remembered. If the next scheduled dose is approaching, skip the missed dose and resume the regular schedule. Doubling up doses to compensate for a missed application isn’t recommended.
Can You Wear Contact Lenses With Combigan?
No. Combigan contains benzalkonium chloride, a preservative that can discolor soft contact lenses. Contact lenses must not be in the eyes during application of this medication.
After applying Combigan eye drops, wait at least 15 minutes before inserting contact lenses. This waiting period allows the preservative to dissipate from the eye surface before lenses come into contact with the treated eye.
How Much Does Combigan Cost?
Brand-name Combigan is a high-cost prescription eye drop without insurance coverage, with the exact retail price varying by pharmacy and geographic location. The cost of an ongoing glaucoma medication significantly affects long-term patient adherence. Expensive medications get skipped. Skipped medications allow pressure to rise.
Financial assistance programs are available from the manufacturer for eligible patients, and discount coupon services such as BuzzRx offer savings on Combigan prescriptions at participating pharmacies. Checking multiple sources before filling a prescription can reduce out-of-pocket costs meaningfully.
Is There a Generic Version of Combigan?
Yes. Generic brimonidine tartrate 0.2% / timolol maleate 0.5% became available after Combigan’s patent expiration in 2022. The generic contains the same active ingredients at identical concentrations and delivers equivalent therapeutic effects.
Generic versions provide the same IOP-lowering benefit at significantly lower cost. Patients currently on brand-name Combigan should ask their pharmacist or prescribing physician about switching to the generic to substantially reduce their monthly prescription expenses.
Is Combigan Worth It?
Combigan is clinically effective at reducing intraocular pressure, achieving 1 to 3 mmHg greater reduction than brimonidine alone and 4.4 to 7.6 mmHg from baseline in a 12-month trial. However, mixed user ratings (5.0/10 on Drugs.com, 42% positive) reflect a real side effect burden. The drug works. It just doesn’t work equally well for everyone.
Combigan works best for patients who need adjunctive therapy on top of a prostaglandin, want the convenience of one bottle instead of two, and don’t have asthma, COPD, or serious cardiac conditions. Patients with those contraindications should explore Simbrinza or dorzolamide-based alternatives with their eye doctor.
Bottom line: patients with well-controlled IOP on a prostaglandin alone don’t need Combigan. Those needing additional pressure lowering benefit clearly from its dual mechanism. With generic brimonidine/timolol available since 2022, the cost barrier that previously limited access has dropped significantly.